A comparison of the effects of tirzepatide and dulaglutide on major kidney events in people with type 2 diabetes: pre-specified exploratory analyses of the SURPASS-CVOT trial.

Saved in:
Bibliographic Details
Title: A comparison of the effects of tirzepatide and dulaglutide on major kidney events in people with type 2 diabetes: pre-specified exploratory analyses of the SURPASS-CVOT trial.
Authors: Zoungas S; School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia; Victorian Heart Institute, Monash University, Melbourne, VIC, Australia. Electronic address: sophia.zoungas@monash.edu., D'Alessio D; Duke University Medical Center, Durham, NC, USA., Pavo I; Eli Lilly and Company, Indianapolis, IN, USA., Bhatt DL; Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Buse JB; University of North Carolina, Chapel Hill, NC, USA., Prato SD; Interdisciplinary Research Center 'Health Science,' Sant'Anna School of Advanced Studies, Pisa, Italy., Kahn SE; Division of Metabolism, Endocrinology and Nutrition, Department of Medicine, VA Puget Sound Health Care System and University of Washington, Seattle, WA, USA., Lincoff AM; Department of Cardiovascular Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, USA., McGuire DK; University of Texas Southwestern Medical Center and Parkland Health System, Dallas, TX, USA., Nauck MA; Diabetes, Endocrinology and Metabolism Section, Department of Medicine, St Josef-Hospital, Katholisches Klinikum Bochum, Ruhr University of Bochum, Bochum, Germany., Nissen SE; Cleveland Clinic Coordinating Center for Clinical Research (C5 Research) and Department of Medicine, Cleveland Clinic, Cleveland, OH, USA., Sattar N; School of Cardiovascular Medicine and Metabolic Health, University of Glasgow, Glasgow, UK., Zinman B; University of Toronto, Lunenfeld-Tanenbaum Research Institute and Mount Sinai Hospital, Toronto, ON, Canada., Ceriello A; IRCCS MultiMedica, Milan, Italy., Stechemesser L; Department of Internal Medicine I, Paracelsus Medical University, Salzburg, Austria., Verhaegen A; Department of Endocrinology, Diabetes and Metabolism, Antwerp University Hospital, Edegem, and ZAS Jan Palfijn, Merksem, Belgium., Broder JC; Monash University Clinical Trials Centre, Monash University, Melbourne, VIC, Australia., Wolfe R; Monash University Clinical Trials Centre, Monash University, Melbourne, VIC, Australia., Miller D; Eli Lilly and Company, Indianapolis, IN, USA., Nishiyama H; Eli Lilly and Company, Indianapolis, IN, USA., Wang X; Eli Lilly and Company, Indianapolis, IN, USA., Weerakkody G; Eli Lilly and Company, Indianapolis, IN, USA., Wiese RJ; Eli Lilly and Company, Indianapolis, IN, USA., Nicholls SJ; Victorian Heart Institute, Monash University, Melbourne, VIC, Australia.
Source: The lancet. Diabetes & endocrinology [Lancet Diabetes Endocrinol] 2026 Jul; Vol. 14 (7), pp. 544-557. Date of Electronic Publication: 2026 May 11.
Publication Type: Journal Article; Randomized Controlled Trial; Comparative Study; Multicenter Study
Journal Info: Publisher: The Lancet, Diabetes & Endocrinology Country of Publication: England NLM ID: 101618821 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2213-8595 (Electronic) Linking ISSN: 22138587 NLM ISO Abbreviation: Lancet Diabetes Endocrinol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2213-8595
DOI:10.1016/S2213-8587(26)00032-X